India Faces Regulatory Gap as Semi-Synthetic Cannabinoids Evade NDPS Act

NDPS Act Definitions Exclude Lab-Derived Compounds

The NDPS Act regulates cannabis, charas, and ganja through plant-origin definitions that don't address semi-synthetic derivatives. Semi-synthetic cannabinoids—compounds chemically modified from natural cannabinoids like CBD or THC—occupy a gray zone under Indian law. The 1985 statute's Section 2(iii) defines cannabis as "the flowering or fruiting tops of the cannabis plant," a botanical standard that doesn't extend to laboratory-synthesized analogs.

Manufacturers can exploit this gap. The Observer Research Foundation report shows they're producing compounds such as delta-8-THC, delta-10-THC, and HHC (hexahydrocannabinol) from hemp-derived CBD through chemical isomerization. These processes yield psychoactive substances that mimic delta-9-THC but don't meet the NDPS Act's plant-based criteria.

Market Growth Outpaces Regulatory Response

Semi-synthetic cannabinoid products have proliferated in Indian markets without clear legal classification or enforcement mechanisms. The compounds appear in vape cartridges, edibles, and wellness products marketed as hemp derivatives. Because the NDPS Act doesn't list specific cannabinoid molecules by chemical structure, enforcement agencies lack statutory authority to regulate these analogs unless they can prove the substance originated from prohibited cannabis plants.

This regulatory vacuum mirrors challenges the United States faced between 2018 and 2023, when the Farm Bill's hemp loophole allowed delta-8-THC to flood state markets ahead of explicit bans. India's framework hasn't yet adapted to this molecular-level evasion.

International Treaty Obligations Complicate Reform

India is a signatory to the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances, treaties that don't account for semi-synthetic cannabinoid chemistry. Updating the NDPS Act to cover synthetic and semi-synthetic analogs would require India to work within these treaty frameworks, which define controlled substances by botanical source or specific chemical schedules, the Observer Research Foundation analysis notes.

The December 2020 United Nations rescheduling of cannabis under the Single Convention didn't resolve the semi-synthetic question. Member states retain discretion to regulate analogs domestically. India hasn't exercised that authority through legislative amendment or administrative rule-making.

Enforcement Challenges Without Molecular Schedules

Law enforcement agencies can't prosecute semi-synthetic cannabinoid cases without statutory language that defines prohibited compounds by chemical structure rather than plant origin. The report documents instances where seized products containing delta-8-THC or HHC were released due to lack of legal basis for prosecution under the NDPS Act. Forensic labs can identify the compounds. Courts have dismissed cases when prosecutors can't cite a specific statutory violation.

Without molecular-level scheduling, India's drug control apparatus is fighting a chemistry war with a botany statute.

This enforcement gap incentivizes manufacturers to shift production toward analogs as regulatory pressure increases on traditional cannabis products.

Proposed Legislative Fixes

The Observer Research Foundation report recommends three statutory amendments to close the loophole:

• Analog scheduling: Amend the NDPS Act to include a catch-all provision for "any substance substantially similar in chemical structure or effect" to delta-9-THC, mirroring the U.S. Federal Analogue Act.
• Molecular definitions: Replace plant-based definitions with IUPAC chemical nomenclature for cannabinoids, allowing enforcement against any THC isomer regardless of source.
• Administrative scheduling authority: Grant the Ministry of Health and Family Welfare or the Narcotics Control Bureau emergency scheduling power for new psychoactive substances, avoiding the lag of parliamentary amendment.

None of these proposals have advanced to draft legislation as of August 2026.

Public Health and Consumer Safety Risks

Unregulated semi-synthetic cannabinoids pose contamination and potency risks identical to those seen in U.S. delta-8-THC markets. Laboratory testing shows that Indian semi-synthetic products often contain residual solvents, heavy metals, and unlabeled delta-9-THC concentrations exceeding legal thresholds in jurisdictions with explicit limits, the report cites. Without Good Manufacturing Practice standards or third-party testing mandates, consumers face exposure to industrial-grade reagents used in isomerization.

Age-verification and packaging requirements are absent, compounding the public health concern—particularly for products marketed as wellness supplements rather than controlled substances.

What Comes Next

The Observer Research Foundation report circulates as India's Ministry of Social Justice and Empowerment conducts a review of the NDPS Act's effectiveness, a process initiated in early 2026. Whether semi-synthetic cannabinoids will be addressed in that review remains unclear. For background on India's broader cannabis policy landscape, see the CannIntel topic hub on India Cannabis Regulation.

Watch for this signal: whether the Narcotics Control Bureau issues an administrative advisory classifying semi-synthetic THC analogs as NDPS Act violations pending legislative reform. That move would mirror the DEA's 2020 interim final rule on hemp-derived delta-8-THC in the United States.